Heather McCoy, APRN
Family · Oklahoma City, OKNPI 1598382392
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,727 of the $9,090 with a category attached, or 85.0%. It is spread thinly across 34 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 426 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Pfizer$1K
- AstraZeneca$948
- Merck$689
- Novartis$644
- E.r. Squibb & Sons, L.L.C.$594
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$1,35015%
- Food & beverage$7,72785%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 41 | $2,002 |
| Pfizer | 62 | $1,034 |
| AstraZeneca | 49 | $948 |
| Merck | 37 | $689 |
| Novartis | 42 | $644 |
| E.r. Squibb & Sons, L.L.C. | 33 | $594 |
| Boehringer Ingelheim | 23 | $483 |
| Johnson & Johnson | 24 | $384 |
| Novo Nordisk | 14 | $370 |
| Cvrx, Inc. | 7 | $304 |
| Lexicon Pharmaceuticals, Inc. | 12 | $250 |
| Bayer | 14 | $249 |
| Esperion Therapeutics, Inc. | 10 | $168 |
| Alnylam Pharmaceuticals Inc. | 6 | $127 |
| Amarin Pharma, Inc. | 12 | $123 |
| Impulse Dynamics (USA) Inc. | 4 | $93 |
| Philips North America LLC | 3 | $78 |
| Boston Scientific | 2 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| GSK | 4 | $53 |
| Abbott | 2 | $37 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $32 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Teleflex LLC | 2 | $26 |
| Althera Pharmaceuticals LLC | 3 | $24 |
| Lundbeck LLC | 1 | $22 |
| Chiesi USA, Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Inari Medical, Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$1,350
- Barostim Neo System$134
- Ozempic$119
How this compares
$9,090 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $123,472 |
| CamzyosMavacamten | 14 | $114,856 |
| XareltoRivaroxaban | 23 | $37,387 |
| EntrestoSacubitril/Valsartan | 28 | $33,342 |
| FarxigaDapagliflozin Propanediol | 18 | $14,956 |
| Atorvastatin Calcium | 109 | $3,244 |
| Metoprolol Succinate | 110 | $2,052 |
| Midodrine Hcl | 12 | $1,843 |
| Pravastatin Sodium | 43 | $1,815 |
| Labetalol Hcl | 28 | $1,705 |
| ClopidogrelClopidogrel Bisulfate | 94 | $1,686 |
| Isosorbide Dinitrate | 24 | $1,480 |
| SotalolSotalol Hcl | 13 | $1,403 |
| Rosuvastatin Calcium | 88 | $1,366 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,034 | $123,472105 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $594 | $114,85614 claims |
| Johnson & JohnsonXarelto | $384 | $37,38723 claims |
| NovartisEntresto | $644 | $33,34228 claims |
| AstraZenecaFarxiga | $948 | $14,95618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.